Gilead’s $3.7 Billion HIV Win! Is GILD Your Next BIG Buy NOW?
Is Gilead Sciences facing a hidden risk, despite its incredible 3.7 billion dollar sales from its flagship HIV treatment, Biktarvy? Investment firm Truist just initiated coverage of Gilead with a Buy rating and a 140 dollar price target, highlighting the robust performance of its HIV portfolio. The company's key HIV therapies like Biktarvy and Descovy continue to post strong sales, and its liver disease treatments also contribute significant growth. While some worry about over-reliance on HIV, Gilead is actively diversifying into oncology and other areas to ensure healthy long-term prospects. This strategic expansion and consistent performance make GILD an intriguing prospect for investors looking at biopharmaceutical growth, so make sure to subscribe to our channel for more exclusive investment insights.
Tags/Hashtags: #gilead #gild #truist #biopharmaceutical #oncology #biktarvy #gild #truist
Leave a Reply